Pharmaceutical technology for liquid formulations.
A patented 7-Valence Salt revolutionizing small molecule repurposing.
Graduating IV to At-Home Use
Improve Health Economics
Renewed IP Protection
Our 7-valence salt technology utilizes molecules that are already FDA-approved. The result: De-risked therapies. At home. Lower costs. Better patient comfort.
Bexson’s breakthrough technology optimizes therapies, that previously damage tissue, to be comfortably delivered subcutaneously.
SeValent™ solves the three factors that commonly hinder subcutaneous formulations: pH, osmolality, and volume.
Offering renewed patent life-cycle with IV level bioavailability to provide health economic cost savings via home and remote care.Learn More About the Benefits
Bexson’s SeVALENT™ technology uses cyclodextrin anionic substitutions as counterions to produce highly soluble multi-valent pharmaceutical salts for patented liquid formulation.
Our current approach makes use of the approved excipient Captisol®, but other variations are possible and protected under Bexson’s broad platform patent allowance.
In July of 2022, the USPTO notified Bexson of an allowance covering the application of SeVALENT™ to any molecule that has an ionizable nitrogen for liquid formulations. This covers any molecule regardless of therapeutic area, including New Chemical Entities (NCEs) not yet invented.
Furthermore, this allowance also applies to “prodrugs,” enabling the innovation of molecules not containing the nitrogen for salt formation.